INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of West Pharmaceutical Services
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In West To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $100,000 in West between February 16, 2023, and February 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 4, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against West Pharmaceutical Services, Inc. ('West' or the 'Company') (NYSE: WST) and reminds investors of the July 7, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/6455/254353_f6d28034a4b6c93d_001full.jpg ]
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) despite claiming strong visibility into customer demand and attributing headwinds to temporary COVID-related product destocking, West was in fact experiencing significant and ongoing destocking across its high-margin High-Value Products portfolio; (b) West's SmartDose device, which was purportedly positioned as a high-margin growth product, was highly dilutive to the Company's profit margins due to operational inefficiencies; (c) these margin pressures created the risk of costly restructuring activities, including the Company's exit from continuous glucose monitoring contracts with long-standing customers; and (d) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially false and/or misleading or lacked a reasonable basis.
The truth about this fraud was revealed over a series of disclosures culminating on February 13, 2025, when West issued extremely weak 2025 revenue and earnings forecasts. West attributed the disappointing guidance in part to contract manufacturing headwinds, including the loss of two major continuing glucose monitoring customers that had begun transitioning to in-house manufacturing of next-generation devices after West 'made the decision to not participate going forward as our financial thresholds cannot be achieved.' West also revealed that its SmartDose wearable injector devices would be 'margin-dilutive' in 2025 and that it would be 'taking steps to improve [its SmartDose] economics, and all options are on the table.'
On this news, West's stock dropped $123.17 per share, a decline of 38 percent, to close at $199.11 on February 13, 2025.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding West's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the West Pharmaceutical Services class action, go to www.faruqilaw.com/WST or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254353
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
This week in Trumponomics: The looming import shortage
Few people pay attention to import and export data, which are among the weedier metrics of the economy's health. But these wonky numbers are giving some startling insights into the challenges everyday shoppers may be facing in a month or two or three. Imports plummeted in April, falling by 20% from the prior month. That's the biggest decline in data going back to 1992. It's considerably worse than the drop in imports at the onset of the COVID-19 pandemic in 2020. Does anybody remember what shopping was like during COVID? Aside from the masks and sanitizer, there were widespread product shortages followed by soaring inflation. People didn't mind at first, since many were stuck at home without much to do. But inflation got quite irksome after a couple of years, and it sank Joe Biden's presidency, along with Democratic electoral odds in 2024. We're not yet facing COVID-style shortages. But we might be if President Trump's trade war drags on through the fall and summer. Imports plunged in April because that's when Trump started slapping new import taxes on practically every product entering the United States. So far, Trump has raised the average tariff tax on imports from 2.5% to about 18%. Read more: What Trump's tariffs mean for the economy and your wallet Prices haven't shot up yet because many of the American companies that import goods saw this coming and stocked up ahead of the Trump tariffs. Imports jumped by a record amount in January and were elevated for the first quarter as a whole. Swollen inventories have kept supplies ample and prices in check. If April represents the new trend line, however, a sharp drop in imports will inevitably lead to higher prices and some shortages. 'The impact of tariffs will continue to reverse progress on returning inflation to 2%,' Goldman Sachs explained in a recent analysis. 'Our forecast reflects a sharp acceleration in most core goods categories, where tariff-related increases in prices will be most acute in consumer electronics, autos, and apparel.' The firm expects overall inflation to rise from 2.3% now to 3.5% by importers are handling the Trump tariffs in a variety of ways. Some are taking normal delivery of goods and paying the higher taxes. We know that because tariff revenue collected by the government soared in April and May. The higher cost of imports will eventually make its way to consumers via higher prices. Many other importers have canceled or postponed orders, hoping that Trump will make trade deals and future tariffs will be lower than current ones. They're also watching two high-profile cases in which courts have said some of Trump's tariffs are illegal, while leaving them in place until appeals play out. Trump himself controls much of what happens next. He has set a July 9 deadline for dozens of countries to initiate trade concessions, or else a punishing round of 'reciprocal' tariffs will go into effect, on top of those Trump has already imposed. Some business owners hope for greater clarity by then, though the July 9 deadline is arbitrary and Trump could change it. Read more: The latest news and updates on Trump's tariffs Once current inventories are gone, the rest of 2025 could be rocky. 'Our perspective in terms of how this will affect manufacturers and workers is that we'll see a replay of the initial COVID shock,' Jason Judd, executive director of the Global Labor Institute at Cornell University, told Yahoo Finance. 'It may not be as severe, depending on the distribution of the pain. If Trump comes back with a 40% tariff on apparel, that would feel like a COVID-era shock.' Trump, for his part, acts like everything is hunky-dory under his watch. 'America is hot!' he said on social media on June 6. 'Border is secure, prices are down. Wages are up!' That came after the employment report for May showed the economy created a middling 139,000 new jobs. Many economists, however, think America is cooling. The pace of job growth has slowed this year, the economy technically shrank in the first quarter, and the stock market has been flat in 2025. Trump's tariffs already seem to be punishing the manufacturing sector, which lost 8,000 jobs in May and is in a three-month slump. If that's 'hot,' a cold Trump economy is likely to be miserable. Rick Newman is a senior columnist for Yahoo Finance. Follow him on Bluesky and X: @rickjnewman. Click here for political news related to business and money policies that will shape tomorrow's stock prices.
Yahoo
an hour ago
- Yahoo
Why Oscar Health, Inc. (OSCR) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Oscar Health, Inc. (NYSE:OSCR) stands against other best-performing stocks on Thursday. Oscar Health snapped a five-day losing streak on Thursday, jumping 10.6 percent to close at $15.65 apiece as investors resorted to bargain-hunting while waiting for more concrete developments on the Trump administration's Medicare Advantage review. Earlier this year, lawmakers passed a $5-trillion tax-and-spending package that shaves as much as $900 billion in Medicaid, which servers over 70 million low-income households. A close up of a patient and a healthcare professional engaging in conversation, showing the company's commitment to patient care. Now, Senate Republicans to broaden savings by looking for supposed inefficiencies in the Medicare program for senior citizens. In the first quarter of the year, Oscar Health, Inc. (NYSE:OSCR) registered a 55-percent increase in attributable net income of $275 million versus the $177 million registered in the same period last year. Revenues rose by 42 percent to $3.046 billion from $2.142 billion year-on-year. Overall, OSCR ranks 5th on our list of best-performing stocks on Thursday. While we acknowledge the potential of OSCR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why Pan American Silver Corp. (PAAS) Soared On Thursday
We recently published a list of . In this article, we are going to take a look at where Pan American Silver Corp. (NYSE:PAAS) stands against other best-performing stocks on Thursday. Pan American Silver rallied for a fifth consecutive day on Thursday, jumping 7.56 percent to close at $28.60 apiece, in line with silver prices hitting a new all-time high. Silver futures rose to as high as $36.27 per troy ounce at intra-day trading on Thursday, its highest since 2012, before closing lower to $35.81 per troy ounce. Silver prices grew alongside gold, as investors' funds flocked to safer assets anew to mitigate the risks from the ongoing trade tensions between the US and China. A large drill in operation deep in a mine, surrounded by the machinery of a modern extraction site. Pan American Silver Corp. (NYSE:PAAS) is a Canada-based silver and gold miner with operations throughout the Americas. In the first quarter of the year, Pan American Silver Corp. (NYSE:PAAS) swung to a net income of $169.3 million from a $30.8 million net loss in the same period last year. Revenues increased by 28 percent to $773.2 million from $601.4 million year-on-year. Overall, PAAS ranks 9th on our list of best-performing stocks on Thursday. While we acknowledge the potential of PAAS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
